ASCO Congress 2018: melanoma treatment

The 2018 ASCO Annual Meeting provided a closer look on the details of studies already presented. In melanoma, the interest was on neoadjuvant treatment options with high pathological response rates as well as updates on large phase III studies in stage IV disease. Further new targets were discussed...

Descripción completa

Detalles Bibliográficos
Autor principal: Richtig, Erika
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Vienna 2018
Materias:
Short Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6280769/
https://www.ncbi.nlm.nih.gov/pubmed/30595751
http://dx.doi.org/10.1007/s12254-018-0455-4
Descripción
Sumario:The 2018 ASCO Annual Meeting provided a closer look on the details of studies already presented. In melanoma, the interest was on neoadjuvant treatment options with high pathological response rates as well as updates on large phase III studies in stage IV disease. Further new targets were discussed focusing on additional drugs to a PD-1 backbone treatment. Another focus was on Merkel cell carcinoma and basal cell carcinomas, giving new data on PD-1 antibody treatments as well as on vismodegib as neoadjuvant therapy.

Ejemplares similares